For example, estrogen receptor 1 (ESR1) mutation detected in the ctDNA of breast cancer (BC) patients pre-treated with aromatase inhibitors correlated with inferior treatment outcome on exemestane, but not on fulvestrant6,7. This evidence concerns the gene ESR1 and breast cancer.